GlassScriptPhysician profile
Jorge Sifuentes
NPI 1841297421
$4,543.07
in general payments reported to CMS, 2019-2025
36 companies · $541 in 2025
The $541 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,797 · 2020: $304 · 2021: $361 · 2022: $337 · 2023: $476 · 2024: $727 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,723 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,723.28 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $975.66 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $391.14 | 2019-2025 | Farxiga, Breztri |
| Pfizer INC. | $358.53 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.30 | 2019-2025 | Jardiance |
| Abbvie INC. | $292.41 | 2019-2025 | Vraylar |
| Lilly USA, LLC | $238.42 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Sunovion Pharmaceuticals INC. | $173.24 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $167.39 | 2019-2023 | Seglentis, Livalo |
| Novartis Pharmaceuticals Corporation | $141.62 | 2019-2020 | |
| Axsome Therapeutics, INC. | $135.51 | 2022-2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $114.64 | 2019 | |
| Amarin Pharma, INC. | $113.69 | 2019 | |
| Antares Pharma, INC. | $108.20 | 2019-2023 | Tlando, Xyosted, Nocdurna |
| Astellas Pharma US INC | $104.74 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $89.70 | 2024-2025 | Voquezna |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $82.38 | 2019-2022 | |
| Verona Pharma, INC. | $81.44 | 2025 | Ohtuvayre |
| Allergan, INC. | $62.19 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.47 | 2021-2023 | Trintellix |
| Supernus Pharmaceuticals, INC. | $58.52 | 2021-2022 | Xyosted, Tlando |
| Clarus Therapeutics INC. | $58.42 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.38 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $49.65 | 2025 | Fanapt |
| Zyla Life Sciences, INC. | $41.92 | 2019-2020 | |
| Eisai INC. | $37.36 | 2019 | |
| Novo Nordisk INC | $26.57 | 2019-2022 | |
| Mylan Specialty L.P. | $26.45 | 2019 | |
| Sumitomo Pharma America, INC. | $25.83 | 2024 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $24.87 | 2025 | Quviviq |
| Avanir Pharmaceuticals, INC. | $18.87 | 2019 | |
| Xeris Pharmaceuticals, INC. | $17.34 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $15.09 | 2021 | |
| Halozyme INC | $13.83 | 2023 | |
| Kyowa Kirin, INC. | $13.06 | 2021 | |
| Amgen INC. | $12.72 | 2019 | |
| Athena Bioscience, LLC | $12.52 | 2024 | Qdolo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Sifuentes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.